| Trial ID: | L0026 |
| Source ID: | NCT05362786
|
| Associated Drug: |
Allogeneic Adipose-Derived Mesenchymal Stem Cells (Msc)
|
| Title: |
Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases
|
| Interventions: |
DRUG: Allogeneic adipose-derived mesenchymal stem cells (MSC)|DRUG: Allogeneic adipose-derived mesenchymal stem cells (MSC)
|
| Outcome Measures: |
Primary: Adverse events and/or serious adverse events, Number of adverse events and/or serious adverse events associated with mesenchymal stem cells intervention, 15 months|Change in eGFR Value, Blood serum estimated glomerular filtration rate (eGFR) reported in milliliters per minute (mL/min), 6 months |
|
| Sponsor/Collaborators: |
Sponsor: LaTonya J. Hickson
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
14
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-07-01
|
| Completion Date: |
2024-07-24
|
| Results First Posted: |
|
| Last Update Posted: |
2024-08-19
|
| Locations: |
Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05362786
|
